References
- Van den Anker JN, Schwab M, Kearns GL. Developmental Pharmacokinetics in Pediatric Clinical Pharmacology. Seyberth HW, Rane A, Schwab M (Eds). Springer 2011. 51–75.
- Hines RN. The ontogeny of drug metabolism enzymes and implications for adverse drug events. Pharmacol Ther 2008;118:250–267.
- Stedman’s Medical Dictionary (ed 26). Baltimore, MD, Williams and Wilkins 1995. 1340.
- Kapur G, Mattoo T, Aranda JV. Pharmacogenomics and renal drug disposition in the newborn. Semin Perinatol 2004;28:132–140.
- Weinshilboum R. Inheritance and drug response. N Engl J Med 2003;348:529–537.
- Impicciatore P, Choonara I, Clarkson A, Provasi D, Pandolfini C, Bonati M. Incidence of adverse drug reactions in paediatric in/out-patients: a systematic review and meta-analysis of prospective studies. Br J Clin Pharmacol 2001;52:77–83.
- Macedo AF, Marques FB, Ribeiro CF, Teixeira F. Causality assessment of adverse drug reactions: comparison of the results obtained from published decisional algorithms and from the evaluations of an expert panel. Pharmacoepidemiol Drug Saf 2005;14:885–890.
- Raju TN, Suresh G, Higgins RD. Patient safety in the context of neonatal intensive care: research and educational opportunities. Pediatr Res 2011;70:109–115.
- Du W, Tutag Lehr V, Lieh-Lai M, Koo W, Ward RM, Rieder MJ, Van den Anker JN et al. An algorithm to detect adverse drug reactions in the neonatal intensive care unit: a new approach. The Journal of Clinical Pharmacology 2012:1–9.
- Shastry BS. Pharmacogenetics and the concept of individualized medicine. Pharmacogenomics J 2006;6:16–21.